With a more profound comprehension of S1P signaling, future research endeavors focusing on the modulation of S1P signaling, along with the development of SPHK or S1PR agonists/antagonists may emerge as a prominent area of interest, potentially leading to innovative therapeutic interventions for pancreatic diseases. Here, SPHK1 is linked to pancreas disorder.